The Current Gap
Acute Myeloid Leukemia (AML) remains a challenging disease with poor long-term outcomes despite significant advancements in treatment.
While new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival remain elusive, particularly for older or unfit patients who cannot tolerate intensive chemotherapy or stem cell transplants ...
Our Breakthrough approach
Cycuria Therapeutics is revolutionizing blood cancer treatment with its proprietary engineered biologics.
Our approach directly and specifically targets leukemic cells and their progenitor stem cells, while preserving healthy blood formation and minimizing systemic toxicity...
High incidence rate for AML,
specially in >60 yrs population
in every 100.000
Poor Overall survival rate
for AML patients
3-year survival rate
TEAM
Our experienced management team brings deep expertise in protein engineering, clinical hemato-oncology and early-stage drug discovery and development
Dr. Nisit Khandelwal
Co-Founder & CEO
Prof. Dr. Philipp J. Jost
Inventor & Co-Founder
John Haurum
Corporate Advisor
Prof. Dr. Felix Wieland
Scientific Advisor
Our Blog
Latest CYCURIA News
Cycuria’s Scientific Founder Co-Authors A Commemorative Review Article on „Cell Death in Cancer“
Prof Philipp Jost, along with other leading experts in the field, authored an invited commemorative review in Cell by Cell Press — titled “𝘾𝙚𝙡𝙡 𝘿𝙚𝙖𝙩𝙝
Cycuria to Present at the AACR Annual Meeting 2026 in San Diego
We are excited to share that our Founder, 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost, will be presenting at the 𝗔𝗔𝗖𝗥 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 in San Diego this
📢 Cycuria’s Scientific Vision Featured in Drug Target Review article
We’re proud to share that 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost , Scientific Founder of Cycuria Therapeutics , is featured in Drug Target Review discussing innovative strategies
Contact Us
Cycuria Therapeutics
Center for Knowledge Transfer II (ZWT II)
Medical Science City Graz
Stiftingtalstraße 14
8010 Graz
Austria